Findings

What do systematic reviews say?

85 questions · 85 findings · 10 reviews · Infectious Diseases

No studies found 13 · 15.3%GRADE not reported 14 · 16.5%Very low 21 · 24.7%Low 18 · 21.2%Moderate 12 · 14.1%High 7 · 8.2%

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).

1 finding from 1 review

Hepatotoxicity:13 Grade 3 and 4 toxicity · HIV‐negative people at risk of TB infection1

Rifampicin probably leads to lower hepatotoxicity:13 Grade 3 and 4 toxicity compared with isoniazid (moderate certainty).

1 finding from 1 review

Adherence · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).

1 finding from 1 review

Hepatotoxicity · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).

1 finding from 1 review